UTHR Q4 2021 Earnings — United Therapeutics Corporation Revenue & Financial Results | Market Cap Arena

UTHRUnited Therapeutics Corporation

$24B

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$415M+7.9% YoY

Gross Profit

$381M91.7% margin

Operating Income

$170M40.9% margin

Net Income

$112M27.0% margin

EPS (Diluted)

$2.35

QoQ Revenue Growth

-6.6%

Cash Flow

Operating Cash Flow

$175M

Free Cash Flow

$104M

Stock-Based Comp.

$45M

Balance Sheet

Total Assets

$5.2B

Total Liabilities

$1.2B

Stockholders' Equity

$4.0B

Cash & Equivalents

$895M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$415M	$385M	+7.9%
Gross Profit	$381M	$350M	+8.7%
Operating Income	$170M	$65M	+160.0%
Net Income	$112M	$99M	+13.6%

Revenue Segments

Tyvaso

$167M40%

Remodulin

$118M28%

Orenitram

$72M17%

Unituxin

$50M12%

Adcirca

$8M2%

Geographic Segments

UNITED STATES

$386M100%